Key result
Inhibition of apoC-III and angptl3 both potently lower triglycerides, but angptl3 inhibition reduces apoB more robustly, suggesting it may confer more favorable cardiovascular disease risk reduction.
Why the study?
Inhibiting apoC-III or angptl3 might reduce residual CVD risk in dyslipidemic patients, but their roles in triglyceride metabolism and early clinical CVD risk reduction potential needed review.
Does inhibiting apoC-III or angptl3 reduce triglycerides, apoB, and cardiovascular disease risk in dyslipidemic patients?
Does inhibiting apoC-III or angptl3 reduce triglycerides, apoB, and cardiovascular disease risk in dyslipidemic patients?
Inhibition of angptl3 and apoC-III potently lowers triglycerides, with angptl3 inhibition showing more robust apoB reduction, highlighting its potential for reducing residual cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May favor angptl3 over apoC-III inhibition clinically; leaves open confirmation of cardiovascular benefit in outcome trials.
PURPOSE OF REVIEW: Apolipoprotein C-III (ApoC-III) and angiopoietin like protein 3 (angptl3) have emerged as key regulators of triglyceride metabolism. Based on Mendelian randomisation studies, novel therapeutic strategies inhibiting these proteins using monoclonal antibodies or gene silencing techniques might reduce residual cardiovascular disease (CVD) risk in dyslipidemic patients. This article aims to review the role of apoC-III and angptl3 in triglyceride metabolism and combine early clinical evidence of CVD reducing potential of these new therapeutic targets. RECENT FINDINGS: Angptl3 inhibition by mAb or antisense therapy has recently completed phase I and II studies, respectively and demonstrate robust apolipoprotein B (apoB) lowering up to 46%. Volanesorsen is an antisense therapy approved for patients with extremely elevated plasma triglyceride levels in which it showed no consistent apoB reduction. However, the GalNAc-conjugated oligonucleotide showed moderate (up to ∼30%) apoB reduction in a phase 1/2a dose-finding study. SUMMARY: Angptl3 and apoC-III are novel targets in lipoprotein metabolism that reduce triglycerides when inhibited. The expected CVD risk reduction may be mediated through reduced triglyceride-rich lipoprotein particle number, reflected by apoB, rather than triglyceride reduction per se. Limited human evidence shows that apoC-III and angptl3 inhibition both potently lower triglycerides, but since angptl3 inhibition reduces apoB more robustly it may be expected to confer more favorable CVD risk reduction.
No takes yet. Share an insight, caveat, or question.
Reeskamp et al. (2020) conducted a review in Dyslipidemia / Hypertriglyceridemia. Apolipoprotein C-III (apoC-III) and angiopoietin like protein 3 (angptl3) inhibitors was evaluated. Inhibition of apoC-III and angptl3 both potently lower triglycerides, but angptl3 inhibition reduces apoB more robustly, suggesting it may confer more favorable cardiovascular disease risk reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: